# US 2011/0301334 A1 · Cysteine engineered antibodies and conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0301334 A1
- Document ID: US20110301334A1
- Status: Published application
- Kind: A1
- Application number: 13/154,672
- Filed: 2011-06-07
- Published: 2011-12-08
- Earliest claimed: 2010-06-08
- Assignees: Genentech, Inc.
- Inventors: Sunil Bhakta; Jagath R. Junutula
- Web page: https://patentgrep.com/patent/US20110301334A1

## CPC

- A61K 47/6817: {Toxins}
- A61K 47/6801: {Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent}
- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/68033: {the drug being a maytansine}
- A61K 47/6811: {the drug being a protein or peptide, e.g. transferrin or bleomycin}
- A61K 47/6829: {Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6855: {the tumour determinant being from breast cancer cell}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61K 51/1051: {the tumor cell being from breast, e.g. the antibody being herceptin}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 5/38: of the suprarenal hormones
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/3092: {against tumour-associated mucins}
- C07K 16/32: against translation products of oncogenes
- A61K 47/6819: {Plant toxins}
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/55: Fab or Fab'
- C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody. Certain highly reactive cysteine engineered antibodies were identified by the PHESELECTOR assay. Isolated cysteine engineered antibodies may be covalently attached to a capture label, a detection label, a drug moiety, or a solid support.

## Claims

### Claim 1

An isolated cysteine engineered antibody comprising a free cysteine amino acid and a sequence in the heavy chain selected from SEQ ID NOS 50-98 or a sequence in the light chain selected from SEQ ID NOS 99-147 wherein a cysteine in the sequence is the free cysteine amino acid.

### Claim 2 (depends on 1)

The isolated cysteine engineered antibody of claim 1 prepared by a process comprising:
(i) mutagenizing a nucleic acid sequence of a parent antibody by replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody;
(ii) expressing the cysteine engineered antibody; and
(iii) isolating the cysteine engineered antibody.

### Claim 3 (depends on 2)

The cysteine engineered antibody of claim 2 wherein mutagenizing comprises site-directed mutagenesis.

### Claim 4 (depends on 2)

The cysteine engineered antibody of claim 2 wherein the cysteine engineered antibody is expressed on a viral particle selected from a phage or a phagemid particle.

### Claim 5 (depends on 2)

The cysteine engineered antibody of claim 2 further comprising:
(i) reacting the cysteine engineered antibody with a thiol-reactive affinity reagent to generate an affinity labelled, cysteine engineered antibody; and
(ii) measuring the binding of the affinity labelled, cysteine engineered antibody to a capture media.

### Claim 6 (depends on 5)

The cysteine engineered antibody of claim 5 wherein the thiol-reactive affinity reagent comprises a biotin moiety.

### Claim 7 (depends on 5)

The cysteine engineered antibody of claim 5 wherein the thiol-reactive reagent comprises a maleimide moiety.

### Claim 8 (depends on 5)

The cysteine engineered antibody of claim 5 wherein the capture media comprises streptavidin.

### Claim 9 (depends on 1)

The cysteine engineered antibody of claim 1 wherein the cysteine engineered antibody is a fusion protein comprising the albumin-binding peptide (ABP).

### Claim 10 (depends on 9)

The cysteine engineered antibody of claim 9 wherein the ABP comprises a sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5.

### Claim 11 (depends on 1)

The cysteine engineered antibody of claim 1 wherein the cysteine engineered antibody is selected from a monoclonal antibody, an antibody fragment, a bispecific antibody, a chimeric antibody, a human antibody, and a humanized antibody.

### Claim 12 (depends on 11)

The cysteine engineered antibody of claim 11 wherein the antibody fragment is a Fab fragment.

### Claim 13 (depends on 11)

The cysteine engineered antibody of claim 11 wherein the cysteine engineered antibody is an anti-HER2 antibody.

### Claim 14 (depends on 1)

The cysteine engineered antibody of claim 1 wherein the cysteine engineered antibody binds to one or more of receptors (1)-(36):
(1) BMPR1B (bone morphogenetic protein receptor-type IB);
(2) E16 (LAT1, SLC7A5);
(3) STEAP1 (six transmembrane epithelial antigen of prostate);
(4) 0772P (CA125, MUC16);
(5) MPF (MPF, MSLN, SMR, megakaryocyte potentiating factor, mesothelin);
(6) Napi3b (NAPI-3B, NPTIIb, SLC34A2, solute carrier family 34 (sodium phosphate), member 2, type II sodium-dependent phosphate transporter 3b);
(7) Sema 5b (FLJ10372, KIAA1445, Mm.42015, SEMA5B, SEMAG, Semaphorin 5b Hlog, sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5B);
(8) PSCA hlg (2700050C12R1k, C530008O16R1k, RIKEN cDNA 2700050C12, RIKEN cDNA 2700050C12 gene);
(9) ETBR (Endothelin type B receptor);
(10) MSG783 (RNF124, hypothetical protein FLJ20315);
(11) STEAP2 (HGNC—8639, IPCA-1, PCANAP1, STAMP1, STEAP2, STMP, prostate cancer associated gene 1, prostate cancer associated protein 1, six transmembrane epithelial antigen of prostate 2, six transmembrane prostate protein);
(12) TrpM4 (BR22450, F1120041, TRPM4, TRPM4B, transient receptor potential cation channel, subfamily M, member 4);
(13) CRIPTO (CR, CR1, CRGF, CRIPTO, TDGF1, teratocarcinoma-derived growth factor);
(14) CD21 (CR2 (Complement receptor 2) or C3DR (C3d/Epstein Barr virus receptor) or Hs.73792);
(15) CD79b (CD79B, CD79β, IGb (immunoglobulin-associated beta), B29);
(16) FcRH2 (IFGP4, IRTA4, SPAP1A (SH2 domain containing phosphatase anchor protein 1a), SPAP1B, SPAP1C);
(17) HER2;
(18) NCA;
(19) MDP;
(20) IL20Rα;
(21) Brevican;
(22) EphB2R;
(23) ASLG659;
(24) PSCA;
(25) GEDA;
(26) BAFF-R (B cell-activating factor receptor, BLyS receptor 3, BR3;
(27) CD22 (B-cell receptor CD22-B isoform);
(28) CD79a (CD79A, CD79α, immunoglobulin-associated alpha, a B cell-specific protein);
(29) CXCR5 (Burkitt's lymphoma receptor 1, a G protein-coupled receptor);
(30) HLA-DOB (Beta subunit of MHC class II molecule (Ia antigen);
(31) P2X5 (Purinergic receptor P2X ligand-gated ion channel 5);
(32) CD72 (B-cell differentiation antigen CD72, Lyb-2);
(33) LY64 (Lymphocyte antigen 64 (RP105), type I membrane protein of the leucine rich repeat (LRR) family);
(34) FcRH1 (Fc receptor-like protein 1);
(35) IRTA2 (Immunoglobulin superfamily receptor translocation associated 2); and
(36) TENB2 (putative transmembrane proteoglycan).

### Claim 15 (depends on 1)

The cysteine engineered antibody of claim 1 wherein the antibody is covalently attached to a capture label, a detection label, a drug moiety, or a solid support.

### Claim 16 (depends on 15)

The cysteine engineered antibody of claim 15 wherein the antibody is covalently attached to a biotin capture label.

### Claim 17 (depends on 15)

The cysteine engineered antibody of claim 15 wherein the antibody is covalently attached to a fluorescent dye detection label.

### Claim 18 (depends on 17)

The cysteine engineered antibody of claim 17 wherein the fluorescent dye is selected from a fluorescein type, a rhodamine type, dansyl, Lissamine, a cyanine, a phycoerythrin, Texas Red, and an analog thereof.

### Claim 19 (depends on 15)

The cysteine engineered antibody of claim 15 wherein the antibody is covalently attached to a radionuclide detection label selected from 3H, 11C, 14C, 18F, 32P, 35S, 64Cu, 68Ga, 86Y, 89Zr, 99Tc, 111In, 123I, 124I, 125I, 131I, 133Xe, 177Lu, 211At, and 213Bi.

### Claim 20 (depends on 15)

The cysteine engineered antibody of claim 15 wherein the antibody is covalently attached to a detection label by a chelating ligand.

### Claim 21 (depends on 20)

The cysteine engineered antibody of claim 20 wherein the chelating ligand is selected from DOTA, DOTP, DOTMA, DTPA and TETA.

### Claim 22 (depends on 15)

The cysteine engineered antibody of claim 15 wherein the antibody is covalently attached to a drug moiety selected from a maytansinoid, an auristatin, a dolastatin, a trichothecene, CC1065, a calicheamicin, enediyne antibiotics, a taxane, and an anthracycline to form an antibody-drug conjugate having Formula I:
Ab-(L-D)p I
where Ab is the antibody, L is a linker, D is the drug moiety, and p is 1, 2, 3, or 4.

### Claim 23 (depends on 22)

The cysteine engineered antibody of claim 22 wherein the antibody-drug conjugate has the structure:

### Claim 24 (depends on 22)

The cysteine engineered antibody of claim 22 wherein D is a maytansinoid having the structure:
wherein the wavy line indicates the covalent attachment of the sulfur atom of D to the linker;
R is independently selected from H, methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-methyl-1-propyl, 2-butyl, 2-methyl-2-propyl, 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, and 3,3-dimethyl-2-butyl; and
m is 1, 2, or 3.

### Claim 25 (depends on 24)

The cysteine engineered antibody of claim 24 wherein D is selected from the structures:

### Claim 26 (depends on 25)

The cysteine engineered antibody of claim 25 having the structure:
wherein n is 0, 1, or 2.

### Claim 27 (depends on 22)

The cysteine engineered antibody of claim 22 wherein D is a monomethylauristatin drug moiety MMAE or MMAF having the structures:

### Claim 28 (depends on 27)

The cysteine engineered antibody of claim 27 wherein the antibody-drug conjugate is selected from the structures:
where Val is valine; Cit is citrulline; and p is 1, 2, 3, or 4.
